The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission. The pharmaceutical company said Friday that ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

The German pharmaceutical company Merck is in talks to acquire the assets of the American SpringWorks Therapeutics Inc. at a price of $47 per share. This is reported in a press release from Merck. As ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...